Intellia Therapeutics (NTLA) Depreciation & Amortization (CF) (2016 - 2026)

Intellia Therapeutics (NTLA) has reported Depreciation & Amortization (CF) for 12 consecutive years, with $2.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) fell 11.93% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $9.5 million (down 7.77% YoY), while the FY2025 annual figure was $9.8 million, down 5.04% from the prior year.
• Depreciation & Amortization (CF) eased to $2.2 million in Q1 2026 per NTLA's latest filing, from $2.4 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $2.6 million in Q2 2024 and bottomed at $1.8 million in Q1 2022.
• Historically, Depreciation & Amortization (CF) has averaged $2.3 million across 5 years, with a median of $2.4 million in 2025.
• Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) increased 21.95% — and 2026, when it decreased 11.93%.
• Intellia Therapeutics' Depreciation & Amortization (CF) stood at $2.1 million in 2022, then gained by 19.77% to $2.5 million in 2023, then gained by 4.06% to $2.6 million in 2024, then retreated by 7.76% to $2.4 million in 2025, then slipped by 7.06% to $2.2 million in 2026.
• Business Quant data shows NTLA's Depreciation & Amortization (CF) at $2.2 million in Q1 2026, $2.4 million in Q4 2025, and $2.4 million in Q3 2025.